Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ERþ/HER2þ breast cancers: Implications to the EXTENET trial

Dhivya R. Sudhan, Luis J. Schwarz, Angel Guerrero-Zotano, Luigi Formisano, Mellissa J. Nixon, Sarah Croessmann, Paula I. Gonzalez Ericsson, Melinda Sanders, Justin M. Balko, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Richard Bryce, Alan Auerbach, Carlos L Arteaga

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Purpose: The phase III ExteNET trial showed improved invasive disease-free survival in patients with HER2þ breast cancer treated with neratinib versus placebo after trastuzumab-based adjuvant therapy. The benefit from neratinib appeared to be greater in patients with ERþ/HER2þ tumors. We thus sought to discover mechanisms that may explain the benefit from extended adjuvant therapy with neratinib. Experimental Design: Mice with established ERþ/HER2þ MDA-MB-361 tumors were treated with paclitaxel plus trastuzumab pertuzumab for 4 weeks, and then randomized to fulvestrant neratinib treatment. The benefit from neratinib was evaluated by performing gene expression analysis for 196 ER targets, ER transcriptional reporter assays, and cell-cycle analyses. Results: Mice receiving "extended adjuvant" therapy with fulvestrant/neratinib maintained a complete response, whereas those treated with fulvestrant relapsed rapidly. In three ERþ/ HER2þ cell lines (MDA-MB-361, BT-474, UACC-893) but not in ERþ/HER2 MCF7 cells, treatment with neratinib induced ER reporter transcriptional activity, whereas treatment with fulvestrant resulted in increased HER2 and EGFR phosphorylation, suggesting compensatory reciprocal crosstalk between the ER and ERBB RTK pathways. ER transcriptional reporter assays, gene expression, and immunoblot analyses showed that treatment with neratinib/fulvestrant, but not fulvestrant, potently inhibited growth and downregulated ER reporter activity, P-AKT, P-ERK, and cyclin D1 levels. Finally, similar to neratinib, genetic and pharmacologic inactivation of cyclin D1 enhanced fulvestrant action against ERþ/HER2þ breast cancer cells. Conclusions: These data suggest that ER blockade leads to reactivation of ERBB RTKs and thus extended ERBB blockade is necessary to achieve durable clinical outcomes in patients with ERþ/HER2þ breast cancer.

Original languageEnglish (US)
Pages (from-to)771-783
Number of pages13
JournalClinical Cancer Research
Volume25
Issue number2
DOIs
StatePublished - Jan 15 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER<sup>þ</sup>/HER2<sup>þ</sup> breast cancers: Implications to the EXTENET trial'. Together they form a unique fingerprint.

  • Cite this

    Sudhan, D. R., Schwarz, L. J., Guerrero-Zotano, A., Formisano, L., Nixon, M. J., Croessmann, S., Gonzalez Ericsson, P. I., Sanders, M., Balko, J. M., Avogadri-Connors, F., Cutler, R. E., Lalani, A. S., Bryce, R., Auerbach, A., & Arteaga, C. L. (2019). Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ERþ/HER2þ breast cancers: Implications to the EXTENET trial. Clinical Cancer Research, 25(2), 771-783. https://doi.org/10.1158/1078-0432.CCR-18-1131